Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus

Table 1 Demographics and medications of patients in the study

Parameter	RA	SLE	OA	Controls
Total numbers	26	11	13	21
Age (years)
Mean	55.1	42.5	71.2	42.6
Range	25–76	27–78	62–79	25–64
Sex (n)
Female	21	10	8	15
Male	5	1	5	6
Duration of disease (years)
Mean	8.1	9.5	3.3	-
Range	0.1–37	2–25	0.5–10	-
Clinical parameter (mean ± SD)
Leukocytes (10⁹/l)	9.5 ± 2.7	4.3 ± 1.1	7.8 ± 2.7	nd
CRP (mg/dl)	3.1 ± 3.0	1.1 ± 0.9	0.5 ± 0.6	nd
ESR (mm/h)	37.5 ± 30.5	34.9 ± 16.7	28.5 ± 19.4	nd
Treatment (n)
None	6	-	-	21
Corticosteroids and/or NSAID	7	-	8^a	-
Anti-TNF-α therapy	13^b	-	-	-
Predisolone	-	11^c	-	-
Cyclophosphamide (i.v.)	-	6	-	-

CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; i.v., intravenous; nd, not determined; NSAID, non-steroidal anti-inflammatory drugs; OA, osteoarthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.
^aTreatment with buprenorphine (1) or tramadol (1); ^btreatment with TNF-α-specific antibodies infliximab (6) or adalimumab (3) (mostly in combination with methotrexate) or with the soluble TNF-α receptor etanercept (2); ^ctreatment with predisolone alone (2), in combination with azathioprine (3), or in combination with cyclophosphamide (6).

ISSN: 1478-6362